Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects

World Journal of Biological Psychiatry

Volumn 14, Issue 7, 2013, Pages 478-489

  Krishnamurthy, Divya ^a   Harris, Laura W ^a   Levin, Yishai ^a,b   Koutroukides, Theodoros A ^a   Rahmoune, Hassan ^a   Pietsch, Sandra ^a   Vanattou Saifoudine, Natacha ^a   Leweke, F Markus ^c   Guest, Paul C ^a   Bahn, Sabine ^a,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ACTH; Biochemical markers; Neuropsychiatry; Psychopathology; Schizophrenia

Indexed keywords

AGOUTI RELATED PROTEIN; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; ARGIPRESSIN; BETA2 GLYCOPROTEIN 1; CALCIUM BINDING PROTEIN; CORTICOTROPIN; GROWTH HORMONE; HYDROCORTISONE; PROLACTIN; PROTEIN SECRETAGOGIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; HYPOPHYSIS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOASSAY; LIPID TRANSPORT; LIQUID CHROMATOGRAPHY; MALE; METABOLISM; MULTIPLEX ANALYTE PROFILING; NUCLEOTIDE SEQUENCE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SCHIZOPHRENIA; STRESS; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; WESTERN BLOTTING;

ADULT; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PITUITARY GLAND; PROTEOMICS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84884248967     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2011.601759     Document Type: Article

References (56)

1. Ackland J, Ratter S, Bourne G, Rees LH. 1983. Proopiomelanocortin peptides in the human fetal pituitary. Regul Pept 6: 51-61.
2. Alberti G, Zimmet P, Shaw J, Grundy SM. 2006. The IDF consensus worldwide definition of the metabolic syndrome. In: Federation ID, editor. Brussels: IDF Communications.
3. Acher R, Chauvet J. 1988. Structure, processing and evolution of the neurohypophysial hormone-neurophysin precursors. Biochimie 70: 1197-1207.
4. Arlt W, Stewart PM. 2005. Adrenal corticosteroid biosynthesis, metabolism, and action. Endocrinol Metab Clin N Am 34: 293-313, viii.
5. Banki CM, Bissette G, Arato M, O' Connor L, Nemeroff CB. 1987. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry 144: 873-877.
6. Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, Cotter D. 2006. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for disease-associated changes. Proteomics 6: 3414-3425.
7. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodological) 57: 289-300.
8. Birkenkamp-Demtroder K, Wagner L, Brandt Sorensen F, Bording Astrup L, Gartner W, Scherubl H, et al. 2005. Secretagogin is a novel marker for neuroendocrine differentiation. Neuroendocrinology 82: 121-138.
9. Brunelin J, d' Amato T, van Os J, Cochet A, Suaud-Chagny MF, Saoud M. 2008. Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizophrenia, their unaffected siblings and controls. Schizophr Res 100: 206-211.
10. Bushe C, Holt R. 2004. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl 47: S67-71.
11. Ciaraldi TP, Mudaliar S, Barzin A, Macievic JA, Edelman SV, Park KS, et al. 2005. Skeletal muscle GLUT1 transporter protein expression and basal leg glucose uptake are reduced in type 2 diabetes. J Clin Endocrinol Metab 90: 352-358.
12. Clark C, Kopala L, Li DK, Hurwitz T. 2001. Regional cerebral glucose metabolism in never-medicated patients with schizophrenia. Can J Psychiatry 46: 340-345.
13. D'Agostino RB. 1986. Tests for Normal Distribution. In: D'Agostino RB, Stepenes MA, editors. Goodness-of-fit techniques. New York: Marcel Decker.
14. Dai T, Patel-Chamberlin M, Natarajan R, Todorov I, Ma J, LaPage J, et al. 2009. Heat shock protein 27 overexpression mitigates cytokine-induced islet apoptosis and streptozotocininduced diabetes. Endocrinology 150: 3031-3039.
15. Engelmann M, Landgraf R, Wotjak CT. 2004. The hypothalamicneurohypophysial system regulates the hypothalamic-pituitaryadrenal axis under stress: an old concept revisited. Front Neuroendocrinol 25: 132-149.
16. Friedland JS, Shattock R, Remick DG, Griffin GE. 1993. Mycobacterial 65-kD heat shock protein induces release of proinflammatory cytokines from human monocytic cells. Clin Exp Immunol 91: 58-62.
17. Gartner W, Lang W, Leutmetzer F, Domanovits H, Waldhausl W, Wagner L. 2001. Cerebral expression and serum detectability of secretagogin, a recently cloned EF-hand Ca(2 -) -binding protein. Cereb Cortex 11: 1161-1169.
18. Gerozissis K. 2008. Brain insulin, energy and glucose homeostasis; genes, environment and metabolic pathologies. Eur J Pharmacol 585: 38-49.
19. Goldman MB, Robertson GL, Luchins DJ, Hedeker D. 1996. The influence of polydipsia on water excretion in hyponatremic, polydipsic, schizophrenic patients. J Clin Endocrinol Metab 81: 1465-1470.
20. Guest PC, Wang L, Harris LW, Burling K, Levin Y, Ernst A, et al. 2010. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry 15: 118-119.
21. Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, Rothermundt M, et al. 2011. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology. 2011 Aug;36(7): 1092-1096
22. Heinrichs M, von Dawans B, Domes G. 2009. Oxytocin, vasopressin, and human social behavior. Front Neuroendocrinol 30: 548-557.
23. Hession C, Osborn L, Goff D, Chi-Rosso G, Vassallo C, Pasek M, et al. 1990. Endothelial leukocyte adhesion molecule 1: direct expression cloning and functional interactions. Proc Natl Acad Sci USA 87: 1673-1677.
24. Huang JT, Wang L, Prabakaran S, Wengenroth M, Lockstone HE, Koethe D, et al. 2008. Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol Psychiatry 13: 1118-1128.
25. Kim JJ, Lee SJ, Toh KY, Lee CU, Lee C, Paik IH. 2001. Identifi- cation of antibodies to heat shock proteins 90 kDa and 70 kDa in patients with schizophrenia. Schizophr Res 52: 127-135.
26. Koller EA, Doraiswamy PM. 2002. Olanzapine-associated diabetes mellitus. Pharmacotherapy 22: 841-852.
27. Krishnamurthy D, Levin Y, Harris L, Umrania Y, Bahn S, Guest PC. 2011. Analysis of the human pituitary proteome by data independent label-free liquid chromatography tandem mass spectrometry. Proteomics 11: 495-500.
28. Kwiterovich Jr PO. 2000. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol 86(12A): 5L-10L.
29. Mai JK, Berger K, Sofroniew MV. 1993. Morphometric evaluation of neurophysin-immunoreactivity in the human brain: pronounced inter-individual variability and evidence for altered staining patterns in schizophrenia. J Hirnforsch 34: 133-154.
30. Martins-de-Souza D, Wobrock T, Zerr I, Schmitt A, Gawinecka J, Schneider-Axmann T, et al. 2010. Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World J Biol Psychiatry 11: 719-728.
31. McDermott E, de Silva P. 2005. Impaired neuronal glucose uptake in pathogenesis of schizophrenia-can GLUT 1 and GLUT 3 deficits explain imaging, post-mortem and pharmacological findings? Med Hypotheses 65: 1076-1081.
32. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, et al. 2008. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 372: 224-233.
33. Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, et al. 2008. 38. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 101: 273-86.
34. Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, et al. 2009. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry 66: 1013-1022.
35. Montaner J, Perea-Gainza M, Delgado P, Ribo M, Chacon P, Rosell A, et al. 2008. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 3: 2280-2287.
36. Onat A, Hergenc G, Sansoy V, Fobker M, Ceyhan K, Toprak S, et al. 2003. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis 168: 81-89.
37. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. 2000. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 45: 21-28.
38. Papadimitriou A, Priftis KN. 2009. Regulation of the hypothalamic- pituitary-adrenal axis. Neuroimmunomodulation 16: 265-271.
39. Pariante CM, Vassilopoulou K, Velakoulis D, Phillips L, Soulsby B, Wood SJ, et al. 2004. Pituitary volume in psychosis. Br J Psychiatry 185: 5-10.
40. Prohaszka Z, Fust G. 2004. Immunological aspects of heat-shock proteins-the optimum stress of life. Mol Immunol 41: 29-44.
41. Ryan MC, Thakore JH. 2002. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 71: 239-257.
42. Ryan MC, Collins P, Thakore JH. 2003. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160: 284-289.
43. Ryan MC, SharifiN, Condren R, Thakore JH. 2004. Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrinology 29: 1065-1070.
44. Schousboe I. 1985. beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 66: 1086-1091.
45. Schwarz MJ, Riedel M, Gruber R. 1999. Ackenheil M, Muller N. Antibodies to heat shock proteins in schizophrenic patients: implications for the mechanism of the disease. Am J Psychiatry 156: 1103-1104.
46. Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG. 2000. Central nervous system control of food intake. Nature 404, 661-671.
47. Silva JC, Denny R, Dorschel CA, Gorenstein M, Kass IJ, Li GZ, et al. 2005. Quantitative proteomic analysis by accurate mass retention time pairs. Anal Chem 77: 2187-2200.
48. Skovhus KV, Bergholdt R, Erichsen C, Sparre T, Nerup J, Karlsen AE, et al. 2006. Identification and characterization of secretagogin promoter activity. Scand J Immunol 64: 639-645.
49. Swatton JE, Prabakaran S, Karp NA, Lilley KS, Bahn S. 2004. Protein profiling of human postmortem brain using 2-dimensional fluorescence difference gel electrophoresis (2-D DIGE). Mol Psychiatry 9: 128-143.
50. Takahashi T, Suzuki M, Velakoulis D, Lorenzetti V, Soulsby B, Zhou SY, et al. 2009. Increased pituitary volume in schizophrenia spectrum disorders. Schizophr Res 108: 114-121.
51. Tsigos C, Chrousos GP. 2002. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 53: 865-871.
52. van der Weerd L, Tariq Akbar M, Aron Badin R, Valentim LM, Thomas DL, Wells DJ, et al. 2010. Overexpression of heat shock protein 27 reduces cortical damage after cerebral ischemia. J Cereb Blood Flow Metab 30: 849-856.
53. von Eckardstein A, Holz H, Sandkamp M, Weng W, Funke H, Assmann G. 1991. Apolipoprotein C-III(Lys58- Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. J Clin Invest 87: 1724-1731.
54. Walsh P, Spelman L, SharifiN, Thakore JH. 2005. Male patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release. Psychoneuroendocrinology 30: 431-437.
55. Yang Y, Wan C, Li H, Zhu H, La Y, Xi Z, et al. 2006. Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Anal Chem 78: 3571-3576.
56. Zhan X, Evans CO, Oyesiku NM, Desiderio DM. 2003. Proteomics and transcriptomics analyses of secretagogin downregulation in human non-functional pituitary adenomas. Pituitary 6: 189-202.